Program overview
Context
Indication: Muscle Invasive Bladder Cancer (MIBC)
Mechanism: Unknown
Modality: Unknown
Sponsor: Qilu Hospital of Shandong University
Low Signal
RC48-ADC combined with toripalimab for bladder-sparing therapy
RC48-ADC combined with toripalimab for bladder-sparing therapy is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 0/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 0/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07201675
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07201675 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | rare_population_signal |